FDA Approves Crizotinib for Treatment of ALK+ Inflammatory Advanced Myofibroblastic Tumors

Article

Patients with ALK-positive inflammatory myofibroblastic tumors can now receive treatment with crizotinib following the agent’s approval by the FDA.

Crizotinib (Xalkori) has received approval from the FDA for the treatment of patients with unresectable, recurrent, or refractory ALK-positive inflammatory myofibroblastic tumors who are 1 year of age or older, according to a press release from the FDA.

The agent was evaluated in multiple clinical trials, including the phase 1/2 ADVL912 trial (NCT00939770) in a younger population of patients with relapsed/refractory solid tumors or anaplastic large cell lymphoma (n = 14), as well as the phase 1 A8081013 trial (NCT01121588) in adult patients solid ALK-positive malignancies with the exception of non–small cell lung cancer (n = 7). The oral drug can be administered at a recommended dose of 250 mg twice daily in adults and 280 mg/m2 twice daily in pediatric patients until progression or unacceptable toxicity.

The overall response rate was 86% (95% CI, 57%-98%) in the ADVL912 trial, with 5 of 7 patients in the A8081013 trial experiencing objective responses. Common adverse effects (AEs) in the pediatric population included vomiting, nausea, diarrhea, abdominal pain, rash, vision disorder, upper respiratory tract infection, cough, pyrexia, musculoskeletal pain, fatigue, edema, constipation, and headache, with common AEs in the adult population consisting of vision disorders, nausea, and edema.

Reference

FDA approves crizotinib for ALK-positive inflammatory myofibroblastic tumor. News release. FDA. July 14, 2022. Accessed July 14, 2022. https://bit.ly/3o10Eij

Recent Videos
Subsequent testing among patients in a prospective study may affirm the ability of cfDNA sequencing to detect cancers in those with Li-Fraumeni syndrome.
cfDNA sequencing may allow for more accessible, frequent, and sensitive testing compared with standard surveillance in Li-Fraumeni syndrome.
STX-478 showed efficacy in patients with advanced solid tumors regardless of whether they had kinase domain or helical PI3K mutations.
STX-478 may avoid adverse effects associated with prior PI3K inhibitors that lack selectivity for the mutated protein vs the wild-type protein.
Phase 1 data may show the possibility of rationally designing agents that can preferentially target PI3K mutations in solid tumors.
Funding a clinical trial to further assess liquid biopsy in patients with Li-Fraumeni syndrome may help with detecting cancers early across the board.
Michael J. Hall, MD, MS, FASCO, discusses the need to reduce barriers to care for those with Li-Fraumeni syndrome, including those who live in rural areas.
The ability of metformin to disrupt mitochondrial metabolism may help mitigate the risk of cancer in patients with Li-Fraumeni syndrome.
It can be hard to get exposure for a new field, but Jessica Cheng, MD, has big plans on how to advance the field of cancer rehabilitation.
Anyone undergoing cancer treatments could benefit from cancer rehabilitation, according to Jessica Cheng, MD.
Related Content